Scolaris Content Display Scolaris Content Display

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Summary of findings for the main comparison. The statistical results of total grade of symptoms or general curative effect in Type I ‐III

The statistical results of trials

in Type I‐III (Student's t‐test or

Chi‐square test or Fisher's exact test)

Total grade of symptoms

before treatment in IP/CP

( P value)

Total grade of symptoms

after treatment in IP/CP

(P value)

The general curative effect after

the treatment in IP/CP

(efficacy/inefficacy)

Hematochezia

Pain in the anal area

Inflammation of perianal mucosa

Perianal venous prolapse

Congestive haemorrhoidal cushions

Haemorrhoids bleeding on contact

Huang 2003

(type I)

IP group: 11/13

CP group: 10/14

(0.751, P>0.05)

IP group: 21/3

CP group: 14/10

(6.715, P<0.05)

IP group: 4/12

CP group: 8/7

(2.620, P>0.05)

IP group: 16/8

CP group: 10/14

(3.021, P>0.05)

IP group:2/11

CP group: 4/6

(0.197, P>0.05)

IP group:2/21

CP group: 2/21

(0.696, P>0.05)

Lu 2005

(type I)

IP group: 25/47

CP group: 15/57

(3.462, P>0.05)

Zheng 2005

(type I)

IP group/ CP group:

9.42±1.71/9.43±1.32

(0.036, P>0.05)

IP group/ CP group:

4.00±1.84/ 5.23±1.88

(3.622, P<0.01)

IP group/ CP group:

0.62±0.88/ 1.00±1.09

(2.101, P<0.05)

IP group/ CP group:

0.30±0.50/ 0.48±0.60

(1.785, P>0.05)

IP group/ CP group:

1.02±0.89/1.37±0.97

(2.059, P<0.05)

IP group/ CP group:

1.02±0.89 / 1.37±0.97

(0.8837, P>0.05)

IP group/ CP group:

0.72±0.67/ 0.90±0.57

(1.585, P>0.05)

He 2006

(type I)

IP group/ CP group:

6.62±2.65/7.17±2.66
(0.732, P>0.05)

IP group/ CP group:

2.76±1.84/ 3.76±2.29

(2.407, P<0.05)

Zhang 2008

(type I)

IP group: 116/52

CP group: 80/50

(1.836, P>0.05)

Zheng 1999

(type II)

IP group: 158/62

CP group: 87/133

(46.427, P<0.001)

Chen 2002

(type II)

IP group: 181/35

CP group: 61/44

(25.154, P<0.001)

IP group: 209/7

CP group: 92/13

(10.10, P<0.001)

Peng 2004

(type II)

IP group: 102/8

CP group: 90/20

(5.893, P<0.05)

Xu 2004

(type II)

IP group: 58/3

CP group: 20/50

(59.856, P<0.001)

IP: intervention group

CP: control group

Figuras y tablas -
Summary of findings for the main comparison. The statistical results of total grade of symptoms or general curative effect in Type I ‐III
Table 1. Table of administration of Chinese medicinal herbs

Type of trials

Number of trials

Herbs in regimen of IP

Medicine (herbs or western medicine) in CP

Route of administration of IP

Peroid of administration of IP

RCT and blind method

Follow time

type I

Huang 2003

Zhixue Capsule (Cortex Fictamni Radicis, Radix Sphporae Flavescentis, there's no specific dosage due to commercial secret)

Zhikang Tablet (there's no specific dosage and herbs due to commercial secret)

oral ad

7 days

RCT with double blind

No

type I

Lu 2005

Fuhuang Tablet (Radix ET Rhizoma Rhei, Radix Sanguisorbae, Fructus Sophorae, Pollen Typhae, there's no specific dosage due to commercial secret)

Zhining Tablet (Radix Sanguisorbae, Cacumen Biotae, Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Scutellariae, Flos Sophorae Immaturus, there's no specific dosage due to commercial secret)

oral ad

7 days

RCT with single blind

No

type I

Zheng 2005

Zhixueningheji (Zhixueheji) (Radix Sanguisorbae, Cacumen Biotae, Cortex Phellodendri, Radix Scutellariae, Prepared Radix Rehmanniae, there's no specific dosage due to commercial secret)

Huaijiao Pill (Radix Sanguisorbae, Radix Sanguisorbae,Radix Scutellariae, there's no specific dosage due to commercial secret)

oral ad

7 days

RCT without blind

No

type I

He 2006

Zhixue Capsule (Cortex Fictamni Radicis, Radix Sphporae Flavescentis, there's no specific dosage due to commercial secret)

Huaijiao Pill (Radix Sanguisorbae, Radix Sanguisorbae,Radix Scutellariae, there's no specific dosage due to commercial secret)

oral ad

7 days

RCT without blind

No

type I

Zhang 2008

Zhixueheji (Radix Sanguisorbae, Cacumen Biotae, Cortex Phellodendri, Radix Scutellariae, Prepared Radix Rehmanniae, there's no specific dosage due to commercial secret)

Zhichuang Tablet (there's no specific dosage and herbs due to commercial secret)

oral ad

30‐45 days

RCT without blind

No

type II

Zheng 1999

Zhixuening Decoction (Radix Sanguisorbae, Radix Astragali sue Hedysari, Herba Schizonepetae, Fresh Radix Rehmanniae, Radix Scutellariae, OS Sepiella seu Sepiae, Radix Boehmeriae, Rhizome Cimicifugae, Radix Angelicae Dahuricae, Radix Paeoniae Alba, Fructus Cannabis, Semen Pruni, there's no specific dosage due to commercial secret)

adrenosem 10mg, vit K4 8mg

oral ad

7 days

RCT without blind

No

type II

Chen 2002

Zhixuekang Decoction (Fructus Cannabis 15g, Semen Pruni 15g, Prepared Radix Rehmanniae 20g, Rhizoma Bletillae 3g, Radix Sanguisorbae 30g, Herba Ecliptae 30g, Radix Codonopsis Pilosulae 30g, Radix Astragali seu Hedysari 30g, Radix Angelicae Sinensis 10g, Rhizoma Coptidis 10g, Flos Lonicerae 20g, Colla Corii Asini 15g, Flos Sophorae 30g, Radix Scrophulariae 20g, Herba Agrimoniae 30g, Fructus Mori 20g, Radix Glycyrrhizae 10g)

adrenosem 10mg, vit K4 4mg, norfloxacin 0.2

oral ad

10 days

RCT without blind

No

type II

Peng 2004

Callicarpa Nudiflora Tablet (there's no specific dosage due to commercial secret)

adrenosem, vit C (without specific dosage)

oral ad

14 days

RCT without blind

2‐6 months

type II

Xu 2004

Subgroup1: blood‐heat (Cacumen Biotae, Radix Sanguisorbae, Fresh Radix Rehmanniae, Cortex Moutan Radicis, Radix Paeonize Rubra, Radix ET Rhizoma Rhei, Flos Sophorae, Rhizoma Coptidis, Radix Scutellariae, Herba Schizonepetae, Radix Glycyrrhizae)

Subgroup 2: damp‐heat (Rhizoma Coptidis, Radix Glycyrrhizae, Radix Sanguisorbae, Radix ET Rhizoma Rhei, Radix Angelicae Sinensis, Cortex Phellodendri, Rhizoma Atractylodis, Radix Ledebouriellae, Flos Sophorae, Radix Gentianae Macrophyllae, Semen Persicae, Rhizoma Alismatis, Radix Rubiae, Gleditsia sinensis Lam)

Subgroup 3: deficiency of blood (Radix Paeonize Rubra, Radix Angelicae Sinensis, Radix Sanguisorbae, Cacumen Biotae, Flos Sophorae, Colla Corri Asini, Raidx Codonopsisi Pilosulae, Rhizoma Atractylodis Macrocephalae, Smilax China L, Prepared Radix Rehmanniae, Radix Astragali seu Hedysari, Rhizoma Ligustici Chuanxiong)

There is no specific dosage due to commercial secret

adrenosem, cefradine (without specific dosage)

oral ad

5 days

RCT without blind

No

ad: administration

IP: intervention group

CP: controlled group

Figuras y tablas -
Table 1. Table of administration of Chinese medicinal herbs
Table 2. Table of the basic information from the included studies

Type of trials

Number of trials

Sample size of patients

Setting of patients

(Male/Female)

Age scope of patients

Type of the haemorrhoids

type I

Huang 2003

48

unclear (unclear)

unclear

IH, MH

type I

Lu 2005

144

unclear (64/78)

37‐58

IH, MH

type I

Zheng 2005

120

outpatient (61/59)

41‐65

unclear

type I

He 2006

100

unclear (46/54)

22‐58

IH, MH

type I

Zhang 2008

298

outpatient and inpatient (154/144)

22‐60

unclear

type II

Zheng 1999

440

outpatient and inpatient

(270/170)

19‐68

unclear

type II

Chen 2002

321

outpatient (237/84)

17‐87

IH, MH

type II

Peng 2004

220

outpatient (0/220)

18‐83

IH, MH

type II

Xu 2004

131

unclear (42/89)

22‐70

IH, MH

IH: internal haemorrhoids

EH: external haemorrhoids

MH: mixed haemorrhoids

Figuras y tablas -
Table 2. Table of the basic information from the included studies